These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 18227159)
1. Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Ruckdeschel EA; Kirkham C; Lesse AJ; Hu Z; Murphy TF Infect Immun; 2008 Apr; 76(4):1599-607. PubMed ID: 18227159 [TBL] [Abstract][Full Text] [Related]
2. Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis. Ruckdeschel EA; Brauer AL; Johnson A; Murphy TF Vaccine; 2009 Nov; 27(50):7065-72. PubMed ID: 19786139 [TBL] [Abstract][Full Text] [Related]
3. Human antibody response to outer membrane protein G1a, a lipoprotein of Moraxella catarrhalis. Adlowitz DG; Sethi S; Cullen P; Adler B; Murphy TF Infect Immun; 2005 Oct; 73(10):6601-7. PubMed ID: 16177336 [TBL] [Abstract][Full Text] [Related]
4. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Blakeway LV; Tan A; Peak IRA; Seib KL Microbiology (Reading); 2017 Oct; 163(10):1371-1384. PubMed ID: 28893369 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model. Smidt M; Bättig P; Verhaegh SJ; Niebisch A; Hanner M; Selak S; Schüler W; Morfeldt E; Hellberg C; Nagy E; Lundberg U; Hays JP; Meinke A; Henriques-Normark B PLoS One; 2013; 8(5):e64422. PubMed ID: 23671716 [TBL] [Abstract][Full Text] [Related]
6. Human serum and mucosal antibody responses to outer membrane protein G1b of Moraxella catarrhalis in chronic obstructive pulmonary disease. Adlowitz DG; Kirkham C; Sethi S; Murphy TF FEMS Immunol Med Microbiol; 2006 Feb; 46(1):139-46. PubMed ID: 16420607 [TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the humoral immune response to Moraxella catarrhalis and Streptococcus pneumoniae surface antigens in children suffering from recurrent acute otitis media and chronic otitis media with effusion. Verhaegh SJ; Stol K; de Vogel CP; Riesbeck K; Lafontaine ER; Murphy TF; van Belkum A; Hermans PW; Hays JP Clin Vaccine Immunol; 2012 Jun; 19(6):914-8. PubMed ID: 22539468 [TBL] [Abstract][Full Text] [Related]
8. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Murphy TF; Brauer AL; Aebi C; Sethi S Infect Immun; 2005 Dec; 73(12):8161-6. PubMed ID: 16299311 [TBL] [Abstract][Full Text] [Related]
9. Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2. Shaffer TL; Balder R; Buskirk SW; Hogan RJ; Lafontaine ER PLoS One; 2013; 8(7):e67881. PubMed ID: 23844117 [TBL] [Abstract][Full Text] [Related]
10. Mapping Protective Regions on a Three-Dimensional Model of the Moraxella catarrhalis Vaccine Antigen Oligopeptide Permease A. Perez AC; Johnson A; Chen Z; Wilding GE; Malkowski MG; Murphy TF Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203544 [TBL] [Abstract][Full Text] [Related]
12. Sulfate-binding protein, CysP, is a candidate vaccine antigen of Moraxella catarrhalis. Murphy TF; Kirkham C; Johnson A; Brauer AL; Koszelak-Rosenblum M; Malkowski MG Vaccine; 2016 Jul; 34(33):3855-61. PubMed ID: 27265455 [TBL] [Abstract][Full Text] [Related]
13. Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen of Moraxella catarrhalis. Otsuka T; Kirkham C; Johnson A; Jones MM; Murphy TF Infect Immun; 2014 Aug; 82(8):3503-12. PubMed ID: 24914218 [TBL] [Abstract][Full Text] [Related]
14. Potential impact of a Moraxella catarrhalis vaccine in COPD. Perez AC; Murphy TF Vaccine; 2019 Sep; 37(37):5551-5558. PubMed ID: 28185742 [TBL] [Abstract][Full Text] [Related]
15. Serum antibody response to Moraxella catarrhalis proteins OMP CD, OppA, Msp22, Hag, and PilA2 after nasopharyngeal colonization and acute otitis media in children. Ren D; Almudevar AL; Murphy TF; Lafontaine ER; Campagnari AA; Luke-Marshall N; Casey JR; Pichichero ME Vaccine; 2015 Oct; 33(43):5809-5814. PubMed ID: 26392013 [TBL] [Abstract][Full Text] [Related]
17. A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges. Perez AC; Murphy TF Hum Vaccin Immunother; 2017 Oct; 13(10):2322-2331. PubMed ID: 28853985 [TBL] [Abstract][Full Text] [Related]
18. Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Yang M; Johnson A; Murphy TF Infect Immun; 2011 Feb; 79(2):846-57. PubMed ID: 21134967 [TBL] [Abstract][Full Text] [Related]
19. Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against Moraxella catarrhalis and nontypeable Haemophilus influenzae. Singh S; Wilson JC; Cripps AW; Massa H; Ozberk V; Grice ID; Peak IR Vaccine; 2020 Jan; 38(2):309-317. PubMed ID: 31668366 [TBL] [Abstract][Full Text] [Related]
20. Persistence of Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease and Regulation of the Hag/MID Adhesin. Murphy TF; Brauer AL; Pettigrew MM; LaFontaine ER; Tettelin H J Infect Dis; 2019 Apr; 219(9):1448-1455. PubMed ID: 30496439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]